Changes in e397925: Removed custom references

				FBXW7.md
			
          @@ -7,9 +7,9 @@ link-citations: true

           ## Overview

           FBXW7 mutations are found in a range of lymphoid malignancies, including B-cell lymphomas. These mutations often include missense mutations, deletions, frameshift mutations and splice-site mutations. 

          -Overall, these mutations are relatively rare in DLBCL and occur more frequently in other solid tumors as well as T-cell acute lymphocytic leukemia.<sup>1</sup> 

          -The most commonly observed mutations in those cancers are the hot spots R465 and R479.<sup>1</sup> 

          -In leukemias, FBXW7 mutations enhance the activity of leukemia-initiating cells by stabilizing oncogenic MYC.<sup>2</sup> Whether they have this role in DLBCL remains to be determined. 

          +Overall, these mutations are relatively rare in DLBCL and occur more frequently in other solid tumors as well as T-cell acute lymphocytic leukemia.<sup>[@akhoondiFBXW7HCDC4General2007]</sup> 

          +The most commonly observed mutations in those cancers are the hot spots R465 and R479.<sup>[@akhoondiFBXW7HCDC4General2007]</sup> 

          +In leukemias, FBXW7 mutations enhance the activity of leukemia-initiating cells by stabilizing oncogenic MYC.<sup>[@kingUbiquitinLigaseFBXW72013]</sup> Whether they have this role in DLBCL remains to be determined. 

           ## Relevance tier by entity

          @@ -36,7 +36,6 @@ In leukemias, FBXW7 mutations enhance the activity of leukemia-initiating cells 

           [[include:mermaid_FBXW7.md]]

           ## References

          -1. *Akhoondi, S., Sun, D., Lehr, N., Apostolidou, S., Klotz, K., Maljukova, A., Cepeda, D., Fiegl, H., Dafou, D., Marth, C., Mueller-Holzner, E., Corcoran, M., Dagnell, M., Nejad, S., Nayer, B., Zali, M., Hansson, J., Egyhazi, S., Petersson, F., Sangfelt, P., Nordgren, H., Grandér, D., Reed, S., Widschwendter, M., Sangfelt, O., & Spruck, C. (2007). FBXW7/hCDC4 is a general tumor suppressor in human cancer.. Cancer research, 67 19, 9006-12 . https://doi.org/10.1158/0008-5472.CAN-07-1320.*

          -2. *King, B., Trimarchi, T., Reavie, L., Xu, L., Mullenders, J., Ntziachristos, P., Aranda-Orgilles, B., Pérez-García, A., Shi, J., Vakoc, C., Sandy, P., Shen, S., Ferrando, A., & Aifantis, I. (2013). The Ubiquitin Ligase FBXW7 Modulates Leukemia-Initiating Cell Activity by Regulating MYC Stability. Cell, 153, 1552-1566. https://doi.org/10.1016/j.cell.2013.05.041.*

          +

           <!-- ORIGIN: zhangGeneticHeterogeneityDiffuse2013 -->

           <!-- DLBCL: zhangGeneticHeterogeneityDiffuse2013 -->

...	...	@@ -7,9 +7,9 @@ link-citations: true
7	7
8	8	## Overview
9	9	FBXW7 mutations are found in a range of lymphoid malignancies, including B-cell lymphomas. These mutations often include missense mutations, deletions, frameshift mutations and splice-site mutations.
10		-Overall, these mutations are relatively rare in DLBCL and occur more frequently in other solid tumors as well as T-cell acute lymphocytic leukemia.<sup>1</sup>
11		-The most commonly observed mutations in those cancers are the hot spots R465 and R479.<sup>1</sup>
12		-In leukemias, FBXW7 mutations enhance the activity of leukemia-initiating cells by stabilizing oncogenic MYC.<sup>2</sup> Whether they have this role in DLBCL remains to be determined.
	10	+Overall, these mutations are relatively rare in DLBCL and occur more frequently in other solid tumors as well as T-cell acute lymphocytic leukemia.<sup>[@akhoondiFBXW7HCDC4General2007]</sup>
	11	+The most commonly observed mutations in those cancers are the hot spots R465 and R479.<sup>[@akhoondiFBXW7HCDC4General2007]</sup>
	12	+In leukemias, FBXW7 mutations enhance the activity of leukemia-initiating cells by stabilizing oncogenic MYC.<sup>[@kingUbiquitinLigaseFBXW72013]</sup> Whether they have this role in DLBCL remains to be determined.
13	13
14	14
15	15	## Relevance tier by entity
...	...	@@ -36,7 +36,6 @@ In leukemias, FBXW7 mutations enhance the activity of leukemia-initiating cells
36	36	[[include:mermaid_FBXW7.md]]
37	37
38	38	## References
39		-1. Akhoondi, S., Sun, D., Lehr, N., Apostolidou, S., Klotz, K., Maljukova, A., Cepeda, D., Fiegl, H., Dafou, D., Marth, C., Mueller-Holzner, E., Corcoran, M., Dagnell, M., Nejad, S., Nayer, B., Zali, M., Hansson, J., Egyhazi, S., Petersson, F., Sangfelt, P., Nordgren, H., Grandér, D., Reed, S., Widschwendter, M., Sangfelt, O., & Spruck, C. (2007). FBXW7/hCDC4 is a general tumor suppressor in human cancer.. Cancer research, 67 19, 9006-12 . https://doi.org/10.1158/0008-5472.CAN-07-1320.
40		-2. King, B., Trimarchi, T., Reavie, L., Xu, L., Mullenders, J., Ntziachristos, P., Aranda-Orgilles, B., Pérez-García, A., Shi, J., Vakoc, C., Sandy, P., Shen, S., Ferrando, A., & Aifantis, I. (2013). The Ubiquitin Ligase FBXW7 Modulates Leukemia-Initiating Cell Activity by Regulating MYC Stability. Cell, 153, 1552-1566. https://doi.org/10.1016/j.cell.2013.05.041.
	39	+
41	40	<!-- ORIGIN: zhangGeneticHeterogeneityDiffuse2013 -->
42	41	<!-- DLBCL: zhangGeneticHeterogeneityDiffuse2013 -->